James George Chopas Sells 783 Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Stock

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) CAO James George Chopas sold 783 shares of the business’s stock in a transaction dated Monday, January 13th. The stock was sold at an average price of $28.70, for a total transaction of $22,472.10. Following the completion of the transaction, the chief accounting officer now directly owns 37,358 shares in the company, valued at $1,072,174.60. This trade represents a 2.05 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.

Apellis Pharmaceuticals Stock Performance

Apellis Pharmaceuticals stock opened at $29.03 on Thursday. Apellis Pharmaceuticals, Inc. has a 1-year low of $24.34 and a 1-year high of $71.90. The company has a current ratio of 4.36, a quick ratio of 3.73 and a debt-to-equity ratio of 1.91. The firm has a market capitalization of $3.61 billion, a PE ratio of -14.30 and a beta of 0.94. The firm’s 50 day simple moving average is $31.86 and its 200 day simple moving average is $33.45.

Apellis Pharmaceuticals (NASDAQ:APLS) last released its quarterly earnings results on Tuesday, November 5th. The company reported ($0.46) earnings per share for the quarter, missing the consensus estimate of ($0.32) by ($0.14). The firm had revenue of $196.83 million during the quarter, compared to the consensus estimate of $200.00 million. Apellis Pharmaceuticals had a negative return on equity of 103.11% and a negative net margin of 34.97%. The company’s revenue for the quarter was up 78.3% compared to the same quarter last year. During the same period in the previous year, the company posted ($1.17) EPS. As a group, analysts expect that Apellis Pharmaceuticals, Inc. will post -1.72 earnings per share for the current fiscal year.

Institutional Trading of Apellis Pharmaceuticals

A number of large investors have recently modified their holdings of APLS. Envestnet Asset Management Inc. raised its stake in Apellis Pharmaceuticals by 42.2% in the second quarter. Envestnet Asset Management Inc. now owns 134,536 shares of the company’s stock valued at $5,161,000 after purchasing an additional 39,931 shares in the last quarter. JPMorgan Chase & Co. increased its holdings in shares of Apellis Pharmaceuticals by 23.3% in the 3rd quarter. JPMorgan Chase & Co. now owns 3,884,730 shares of the company’s stock worth $112,036,000 after buying an additional 735,160 shares during the last quarter. Profund Advisors LLC raised its position in shares of Apellis Pharmaceuticals by 90.7% during the 2nd quarter. Profund Advisors LLC now owns 42,968 shares of the company’s stock valued at $1,648,000 after buying an additional 20,435 shares in the last quarter. Algert Global LLC lifted its holdings in shares of Apellis Pharmaceuticals by 137.8% during the 2nd quarter. Algert Global LLC now owns 123,628 shares of the company’s stock worth $4,742,000 after acquiring an additional 71,650 shares during the last quarter. Finally, Edgestream Partners L.P. lifted its holdings in shares of Apellis Pharmaceuticals by 240.4% during the 2nd quarter. Edgestream Partners L.P. now owns 54,572 shares of the company’s stock worth $2,093,000 after acquiring an additional 38,541 shares during the last quarter. Institutional investors own 96.29% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on APLS. Robert W. Baird dropped their target price on shares of Apellis Pharmaceuticals from $92.00 to $55.00 and set an “outperform” rating on the stock in a research note on Thursday, November 7th. HC Wainwright reiterated a “buy” rating and issued a $57.00 price objective on shares of Apellis Pharmaceuticals in a research note on Tuesday. Citigroup reduced their price objective on Apellis Pharmaceuticals from $63.00 to $51.00 and set a “buy” rating for the company in a report on Wednesday, November 6th. The Goldman Sachs Group lowered Apellis Pharmaceuticals from a “buy” rating to a “neutral” rating and set a $36.00 target price on the stock. in a research note on Tuesday, December 17th. Finally, William Blair started coverage on Apellis Pharmaceuticals in a research note on Wednesday, October 16th. They set an “outperform” rating for the company. Eight equities research analysts have rated the stock with a hold rating, ten have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat, Apellis Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus target price of $46.65.

About Apellis Pharmaceuticals

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).